Drugs / apricoxib

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00569114 Oct 2007 → Apr 2009 non-small cell lung carcinoma Tragara Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05841550 May 2023 → May 2027 expected smoldering plasma cell myeloma Oslo University Hospital Recruiting No outcome recorded
Phase 1/2 NCT02261714 Dec 2012 → May 2019 pancreatic adenocarcinoma Targovax ASA Completed No outcome recorded
Phase 25 trials
Phase 2 NCT05638698 Dec 2022 → Dec 2024 overdue neoplasm University of Kansas Medical Center Active not recruiting No outcome recorded
Phase 2 NCT00771953 Nov 2008 → May 2012 non-small cell lung carcinoma University of Maryland, Baltimore Completed No outcome recorded
Phase 2 NCT00709826 Aug 2008 → Jun 2010 malignant pancreatic neoplasm Tragara Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT00657137 Apr 2008 → Sep 2009 breast cancer Tragara Pharmaceuticals, Inc. Terminated No outcome recorded
Phase 2 NCT00652340 Apr 2008 → Jun 2010 non-small cell lung carcinoma Tragara Pharmaceuticals, Inc. Completed No outcome recorded
Phase not applicable1 trial
NCT01532362 Nov 2011 → May 2012 non-small cell lung carcinoma Jonsson Comprehensive Cancer Center Terminated No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as apricoxib ClinicalTrials.gov intervention name — accepted as the source's own label NCT00657137
4

NCT00709826

NCT00652340

NCT01532362

NCT00771953

Known as CS-706 ChEMBL registry synonym — accepted as the source's own label CHEMBL1835207
Known as R-109339 ChEMBL registry synonym — accepted as the source's own label CHEMBL1835207
Known as TG01 “Drug: TG01NCT00569114
3

NCT05638698

NCT05841550

NCT02261714

Action Inhibit “apricoxib, a novel COX-2 inhibitor” PMID 24736085 Apr 2014
1

“Cyclooxygenase-2 inhibitor” CHEMBL1835207

Modality Small molecule CHEMBL1835207
Modality Vaccine “TG01 vaccineNCT05638698
Route Oral “given orally” NCT00569114
Target PTGS2 “Cyclooxygenase-2 inhibitor” CHEMBL1835207